Gsa Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 76.17%
(FY 2023)
- Ebitda 76.17%
(FY 2023)
- Net Worth -0.63%
(FY 2023)
- Total Assets %
(FY 2023)
About Gsa Bio Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pramodkumar Tripathi, Gaurishankar Chaubey, and Ashok Singh serve as directors at the Company.
- CIN/LLPIN
U74900MH2013PTC251457
- Company No.
251457
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Dec 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Gsa Bio Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramodkumar Tripathi  | Director | 02-Jan-2014 | Current |
| Gaurishankar Chaubey | Director | 27-Dec-2013 | Current |
| Ashok Singh | Director | 27-Dec-2013 | Current |
Financial Performance of Gsa Bio Pharma.
Gsa Bio Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 76.17% increase in profit. The company's net worth dipped by a decrease of 0.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gsa Bio Pharma?
In 2023, Gsa Bio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Team Hr Gsa Private LimitedActive 11 years 10 monthsGaurishankar Chaubey and Ashok Singh are mutual person
Medi-Aid Healthcare LlpActive 7 years 7 monthsGaurishankar Chaubey and Ashok Singh are mutual person
- Team Gsa Foods And Beverages LlpActive 5 years 9 months
Gaurishankar Chaubey and Ashok Singh are mutual person
- United Team Hr Consultants Private LimitedActive 13 years 4 months
Gaurishankar Chaubey is a mutual person
- Team Armor Four Shield Private LimitedActive 6 years 2 months
Gaurishankar Chaubey is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gsa Bio Pharma?
Unlock and access historical data on people associated with Gsa Bio Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gsa Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gsa Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
